| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Generated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year |
| 10 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Other Events
Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMIS... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 5, 2026, by and among Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the Persons li... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position Your publication date and time will appear here. | Source: Tarsus Pharmaceuticals, Inc Adds a potential blockbuster opportunity with gildeu... |
| 13 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) announced that Aziz Mottiwala would be leaving his role as the Company’s Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a ne... |
| 08 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of ... |
| 29 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 25, 2026, Tarsus Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the S... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year |
| 23 Feb 2026 |
8-K: Results of Operations and Financial Condition
Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year |
| 18 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors IRVINE, Calif., Feb. 18, 2026 – Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Building the Future of Eye Care January 2026 Vivian, an XDEMVY patient. |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Delivered quarterly XDEMVY® net sales of approximately $119 million, up |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, Tarsus Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the S... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients |
| 18 Mar 2025 |
8-K: Other Events
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), previously disclosed that it had entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Barclay... |
| 13 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with Goldman Sachs & Co. LLC (“Goldman”), BofA Securities, Inc. (“BofA”), Barclays Capital Inc. (“Barclays”) and each of the other underwriters ... |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch |
| 17 Jan 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 15, 2025, Rosemary Crane, a member of the Board of Directors (the “Board”) of Tarsus Pharmaceuticals, Inc. (the “Company”) notified the Company of her resignation as a member of the Board and any committees of the Board, effec... |
Loading...